Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Oct 20;109(3):djw225.
doi: 10.1093/jnci/djw225. Print 2017 Mar.

Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial

Scott P Kelly  1 , Barry I Graubard  1 , Gabriella Andreotti  1 , Naji Younes  1 , Sean D Cleary  1 , Michael B Cook  1
Affiliations
Randomized Controlled Trial

Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial

Scott P Kelly et al. J Natl Cancer Inst. .

Abstract

Background: Evidence suggests that obesity in adulthood is associated with increased risk of "clinically significant" prostate cancer. However, studies of body mass index (BMI) across the adult life course and prostate cancer risks remain limited.

Methods: In a prospective cohort of 69 873 men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, we examined associations of prediagnostic BMI across the adult life course with risk of incident prostate cancer and fatal prostate cancer (prostate cancer-specific mortality). At 13 years of follow-up, we identified 7822 incident prostate cancer cases, of which 3078 were aggressive and 255 fatal. BMI trajectories were determined using latent-class trajectory modeling. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).

Results: BMI at age 20 years, 50 years, and baseline questionnaire (mean age = 63 years) were associated with increased risks of fatal prostate cancer (HRs = 1.27-1.32 per five-unit increase). In five BMI trajectories identified, fatal prostate cancer risk was increased in men who had a normal BMI (HR = 1.95, 95% CI = 1.21 to 3.12) or who were overweight (HR = 2.65, 95% CI = 1.35 to 5.18) at age 20 years and developed obesity by baseline compared with men who maintained a normal BMI. Aggressive and nonaggressive prostate cancer were not associated with BMI, and modest inverse associations were seen for total prostate cancer.

Conclusions: Our results suggest that BMI trajectories during adulthood that result in obesity lead to an elevated risk of fatal prostate cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Prediagnostic body mass index trajectories among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Each trajectory was modeled using quadratic polynomials. Solid lines indicate the trajectory, dashed lines indicate the lower and upper bound 95% confidence intervals of the trajectory. BMI = body mass index.
See this image and copyright information in PMC

References

    1. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA . 2012;307(5):491–497. - PubMed
    1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557–567. - PMC - PubMed
    1. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: Weighing the evidence. Eur Urol. 2013;63(5):800–809. - PMC - PubMed
    1. Cao Y, Ma J. Body Mass Index, Prostate cancer–specific mortality, and biochemical recurrence: A systematic review and meta-analysis. Cancer Prev Res. 2011;4(4):486–501. - PMC - PubMed
    1. Zhong S, Yan X, Wu Y, et al. Body mass index and mortality in prostate cancer patients: A dose-response meta-analysis. Prostate Cancer Prostatic Dis. 2016;19(2):122–31. - PubMed

Publication types

Substances